Evolocumab: what it treats, how to take it, side effects
Last updated September 3, 2026.
Evolocumab (brand name Repatha) is a PCSK9-inhibitor injection that lowers LDL cholesterol by about 60% on top of statins. Approved in 2015, it is for people whose cholesterol stays dangerously high despite maximal statin therapy, or who have inherited cholesterol disorders, and it has hard cardiovascular-outcome data behind it.
What does it treat?
Established cardiovascular disease, to cut the risk of heart attack, stroke, and certain procedures, and primary high cholesterol including heterozygous and homozygous familial hypercholesterolemia (HoFH, in adults and children 10 and older). It disables the PCSK9 protein so the liver keeps more LDL receptors active and pulls more cholesterol out of the blood. It is an add-on, not a replacement: statins and diet stay in place.
How do you take it?
A subcutaneous injection you give yourself: 140 mg every 2 weeks or 420 mg once monthly (the monthly dose given as three consecutive injections or one on-body infuser). It lives in the refrigerator, warms to room temperature 30 minutes before injecting (45 for the on-body infuser), and goes into the thigh, abdomen, or upper arm, rotating sites. Missed dose: inject within 7 days of the missed date and resume your schedule; past 7 days, skip and reset. Training happens at the first dose in the clinic.
Side effects to know
- Common: injection-site reactions (redness, pain, bruising), cold-like symptoms, flu, back pain, and muscle aches, with rates barely above placebo in trials.
- Serious: hypersensitivity reactions including angioedema; a serious allergic reaction means stopping the drug. Notably, very low LDL levels in trials did not produce the cognitive or diabetes signals people worried about, though diabetes incidence is watched.
Who should not take it?
Anyone with a prior serious hypersensitivity reaction to it. Pregnancy and breastfeeding are doctor conversations, since formal data is thin. It is not a statin substitute for people who simply dislike statins; the label positions it for those with disease or familial cholesterol already on maximal tolerated therapy, and insurers enforce that. Latex-sensitive patients should mention it, as some device components contain dry natural rubber.
When is it an emergency?
Call 911 for swelling of the face, lips, or throat, trouble breathing, or a severe full-body rash after an injection. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
How much will it lower my cholesterol?
About 60% on top of a statin, reliably. An LDL of 138 typically lands in the 40s to 50s. In the FOURIER outcome trial, that reduction translated into fewer heart attacks, strokes, and revascularizations in patients with established disease, which is the evidence insurers and guidelines point to.
Is it a statin replacement?
No. It is layered on top of the highest statin dose you can tolerate, plus usually ezetimibe, and the statin keeps working underneath. True statin intolerance (not preference) is the one scenario where it anchors therapy without a statin, and that is a documented, clinician-adjudicated status.
Does lowering LDL that far cause problems?
The fear was cognitive effects, hemorrhagic stroke, and diabetes from very low LDL. Years of trial and follow-up data have not borne out meaningful harm: no cognitive signal, no hemorrhagic-stroke increase, and a small diabetes-signal watch in predisposed patients. Very low LDL appears, so far, to be safe and beneficial in high-risk patients.
What is the difference between evolocumab and alirocumab?
Same target (PCSK9), same ballpark LDL reduction, same every-2-weeks backbone. The practical differences: evolocumab offers a once-monthly 420 mg option via on-body infuser or three injections, and alirocumab offers a lower 75 mg starting dose with titration to 150 mg. Choice usually comes down to formulary, device preference, and dosing schedule.
Why does it cost so much, and will insurance cover it?
It is a monoclonal antibody, so manufacturing is expensive and list prices run in the hundreds per month. Coverage for post-event patients with LDL above threshold on maximal therapy is common but paperwork-heavy: expect prior authorization documenting your event, your LDL, and your current regimen. Manufacturer copay programs often zero out the patient cost once approved.
Can I travel with it?
Yes. It tolerates room temperature for up to 30 days per the label's stability guidance, so a cooled travel pack handles longer trips. Keep it out of heat and freezing, keep the original packaging for light protection, and never shake the syringe.